Cell cycle regulatory kinase modulators: interim progress and issues

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Prior review of cell cycle inhibitors at the National Cancer Institute (NCI).
• Ongoing development and application of novel anti-cancer molecules.
• Identification of potential therapeutic targets within cell cycle regulation.

Purpose of the Study:

• To update progress on cell cycle inhibitors and related drug discovery efforts.
• To review advancements in targeting cell cycle regulatory kinases.
• To highlight emerging strategies in cancer drug development.

Main Methods:

• Review of preclinical and early clinical data for cell cycle inhibitors.
• Analysis of structural data for kinase inhibitors.
• Exploration of drug screening strategies for novel targets.

Main Results:

• Preliminary activity of flavopiridol observed in chronic leukemias, potentially via non-cell cycle-related CDK inhibition.
• Initiation of early phase trials for UCN-01, including combination studies with cytotoxics.
• Refined screening strategies based on emerging structural data for kinases.

Conclusions:

• Continued progress in developing cell cycle inhibitors for cancer therapy.
• Potential of targeting transcriptional regulation through CDKs in leukemia.
• Expanding drug discovery focus to include aurora kinases alongside CDKs and CHK kinases.